Development Pipeline

 

Since 2000, MediciNova, Inc. has built its portfolio of product candidates by acquiring product rights through license agreements primarily with mid-sized Japanese pharmaceutical companies. MediciNova currently has eight compounds for ten different therapeutic indications including multiple sclerosis, acute exacerbations of asthma and exacerbations of COPD, asthma, interstitial cystitis, cancer, Generalized Anxiety Disorder, preterm labor, urinary incontinence and thrombotic disorders. MediciNova's current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations and MN-166 for the treatment of multiple sclerosis, and either pursue development independently, in the case of MN-221, or establish a strategic collaboration to support further development in the United States, in the case of MN-166. MediciNova will seek to monetize its other product candidates at key value inflection points.